Humanin and HNG: Evidence, Safety, and Research Status

Humanin is a short mitochondrial-derived peptide first reported in 2001 after a functional screen for factors that protected cultured neuronal cells from Alzheimer disease-related insults. It is scientifically interesting, but that discovery did not establish Humanin as a treatment for Alzheimer disease, aging, heart disease, or any other condition.

Short answer

• Native Humanin is commonly described as a 24-amino-acid peptide associated with the mitochondrial MT-RNR2 region.
• HNG is an engineered Humanin analog in which serine at position 14 is replaced by glycine. Humanin and HNG are not interchangeable names.
• The direct intervention evidence is preclinical: cultured cells, worms, and animal models.
• A frequently cited cardiac study tested HNG in a small group of aging female mice. It did not test native Humanin in people.
• Human studies have mainly measured endogenous Humanin or examined genetic and health associations. Observational associations are not treatment evidence.
• The ClinicalTrials.gov Humanin records identified in this review measure Humanin as a biomarker; they do not administer native Humanin or HNG.
• Human safety, pharmacokinetics, effective exposure, immunogenicity, and long-term outcomes for an administered Humanin or HNG product remain unestablished.

This page is an evidence guide, not a dosing or administration protocol.

Native Humanin, HNG, and a retail product are different things

Exact sequence matters. A paper using HNG cannot support a claim about native Humanin merely because both names appear in the same abstract. Likewise, an endogenous biomarker association cannot establish the effects of administering a synthetic product.

Evidence map

The practical conclusion is narrow: Humanin biology is credible enough to study, but evidence for using an administered Humanin or HNG product in people is not established.

What the original neuroprotection work showed

The original 2001 report used a functional expression screen and cultured neuronal cells exposed to selected familial Alzheimer disease genes or amyloid-beta-related insults. The researchers identified a cDNA encoding a short peptide they named Humanin and reported protection within those experimental systems.

That study is a discovery paper. It supports a cell-survival hypothesis; it does not show that Humanin reaches the human brain after administration, changes cognition, slows dementia, or is safe for people. Later reviews describe multiple proposed extracellular and intracellular pathways, but proposed mechanisms do not substitute for controlled human outcomes.

What the aging-heart study actually tested

The cardiac-fibrosis paper often cited in marketing evaluated HNG, not native Humanin, in aging female C57BL/6N mice. The reported groups were small: eight old mice received HNG, six old mice served as controls, and five young mice were used as a comparison group. Researchers reported lower measures of interstitial fibrosis, fibroblast proliferation, selected signaling markers, and apoptosis in the HNG-treated old mice.

Those findings are preclinical and hypothesis-generating. They do not establish prevention or reversal of cardiac fibrosis in humans. Important translation questions remain:

• whether native Humanin would behave like HNG;
• whether the same findings would reproduce in larger, blinded studies and across sexes;
• which exposure produced the tissue effects;
• whether repeated exposure creates toxic, immune, metabolic, or cancer-related risks; and
• whether a tissue-marker change leads to a meaningful clinical outcome.

The PubMed record also reports that several authors were consultants for CohBar, a company developing mitochondrial-derived peptide therapeutics. A disclosed relationship does not invalidate a result, but it belongs in an evidence appraisal.

Aging and lifespan claims need several distinctions

A 2020 study connected Humanin biology with lifespan and healthspan across several model systems. Humanin overexpression extended lifespan in C. elegans, and mouse experiments reported selected metabolic and inflammatory findings. The same paper also examined human cohorts, including associations involving circulating Humanin and centenarian offspring.

These are different evidence types:

1. genetic expression in worms;
2. intervention or transgenic work in mice; and
3. observational measurements in people.

They cannot be combined into the claim that Humanin supplementation extends human life. Human longevity associations may reflect underlying mitochondrial function, genetics, health status, medication, age, assay behavior, or other factors. They do not show what happens when a person receives an external peptide.

What the human evidence can—and cannot—tell us

Human studies have reported disease-specific differences in circulating Humanin and other mitochondrial stress signals. A 2020 mitokine study, for example, found patterns that varied across disease groups rather than one universal “more is better” relationship. A 2024 genetic study linked a Humanin P3S variant with selected longevity and cognitive outcomes among APOE4 carriers.

These studies can help researchers generate biomarker and mechanism hypotheses. They cannot establish:

• a target blood concentration for health or longevity;
• that changing a Humanin level will change an outcome;
• the dose, route, formulation, or schedule of an administered product;
• treatment of cognitive decline, metabolic disease, cardiac fibrosis, or aging; or
• the safety of native Humanin, HNG, or another analog.

ClinicalTrials.gov record NCT06105229 is a useful example. It is an observational study designed to compare plasma Humanin concentration in people with acute kidney injury and healthy controls. Humanin is measured, not administered. Other registry records found in the search similarly evaluate endogenous Humanin in conditions such as chronic obstructive pulmonary disease or reproductive health.

Safety and regulatory limits

Preclinical activity does not define a safe human product. For externally supplied Humanin or HNG, the sources reviewed do not establish clinical pharmacokinetics, a therapeutic window, repeated-dose safety, immunogenicity, reproductive risk, carcinogenic risk, drug interactions, or validated monitoring.

Potentially protective signaling is not automatically beneficial in every context. Humanin has been discussed in cancer biology as both a stress-response peptide and a possible contributor to tumor-cell survival or treatment resistance. That uncertainty is another reason not to convert cell-survival findings into general wellness claims.

FDA's Drugs@FDA database is the authoritative place to verify U.S. drug approvals and labeling. A compound's absence from an FDA safety-risk list, a seller's use of “research use only,” or the existence of a laboratory paper does not demonstrate approval, lawful clinical use, product quality, or safety.

Anyone considering an unapproved product should discuss the uncertainty with a licensed clinician. This guide does not provide a self-experimentation protocol.

How to evaluate a Humanin or HNG product claim

Before connecting a paper to a product, verify every link in the chain:

1. Identity: Is the claimed material native Humanin, HNG, or another analog?
2. Sequence and form: Does the sequence, modification, salt or counterion, and formulation match the cited study?
3. Amount: Was content or assay measured, rather than inferred from powder weight?
4. Purity and impurities: Is there a lot-matched chromatogram and an orthogonal identity method?
5. Microbiological quality: If a route that requires sterility is implied, are sterility and endotoxin controlled with appropriate methods?
6. Stability: Do product-specific data support storage, shipping, and in-use claims?
7. Clinical relevance: Is the cited evidence an administered human intervention with meaningful outcomes, or a cell, animal, or biomarker study?

See the source directory, sourcing policy, and research methodology for how this wiki evaluates evidence. The use-case directory separates research categories from treatment claims.

Related guides

• Humanin compound profile
• Interventions for the hallmarks of aging
• Peptides promoted for brain health
• Peptide quality and sourcing
• How to read peptide research

What better evidence would look like

Translation would require a characterized product, validated identity and dose, preclinical toxicology, human pharmacokinetic and safety work, and prospectively registered controlled trials. Those trials would need a prespecified population, appropriate comparator, clinically meaningful outcomes, adequate follow-up, and transparent adverse-event reporting.

Until then, the accurate summary is simple: Humanin and HNG are promising research subjects, not established human longevity, cardiac, metabolic, or neuroprotective therapies.

References

1. Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. Proc Natl Acad Sci U S A. 2001. PubMed
2. Maximov V, et al. Mitochondrial 16S rRNA gene encodes a functional peptide, a potential drug for Alzheimer's disease and target for cancer therapy. Med Hypotheses. 2002. PubMed
3. Yamagishi Y, et al. Identification of essential amino acids in Humanin, a neuroprotective factor against Alzheimer's disease-relevant insults. Peptides. 2004. PubMed
4. Qin Q, et al. Chronic treatment with a Humanin analogue, HNG, attenuates myocardial fibrosis and apoptosis in aging mice. Am J Physiol Heart Circ Physiol. 2018. PubMed
5. Klein LE, et al. Humanin protects against doxorubicin-induced cardiotoxicity in mice. JACC Basic Transl Sci. 2018. PubMed
6. Yen K, et al. The mitochondrial derived peptide Humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020. PubMed
7. Conte M, et al. Human aging and longevity are characterized by high levels of mitokines. J Gerontol A Biol Sci Med Sci. 2021. PubMed
8. Kim SJ, et al. Humanin P3S variant and longevity and cognitive outcomes in APOE4 carriers. 2024. PubMed
9. Shokolenko IN, Alexeyev MF. Mitochondrial-derived peptide Humanin in cancer and degenerative disease. Expert Opin Ther Targets. 2019. PubMed
10. ClinicalTrials.gov. Clinical Value of Plasma Humanin in Acute Kidney Injury (NCT06105229). Study record
11. FDA. Drugs@FDA: FDA-Approved Drugs

Evidence and registry status checked August 29, 2026. Registry records and regulatory status can change.